Niagen Bioscience (NAGE) corporate presentation summary

Market opportunity and growth drivers

• Significant market opportunity in human and pet nutrition, IV/injectables, cosmetics, and pharmaceuticals, with the global anti-aging market expected to surpass $120B by 2030, growing at a 7% CAGR from 2025-2030.

• Gen Z and Millennials drive 41% of wellness spend, supporting long-term growth in the $500B U.S. wellness market.

• Strategic partnerships with blue chip companies like Nestle HealthScience and Watsons expand distribution and brand reach.

• E-commerce represents over 50% of business, with a 66% CAGR since 2017.

• Expansion into new verticals and supply chain efficiencies have enhanced gross margins, reaching 65% in Q2'25.

Product innovation and scientific leadership

• Developed Niagen®, a patented NAD+ booster, and Tru Niagen®, the #1 NAD+ healthy aging supplement in the U.S.

• Product portfolio includes oral supplements, IV/injectables, and upcoming topical/skincare products.

• Niagen IV offers up to 75% faster infusion time and minimal side effects compared to traditional NAD+ IV, targeting a $300M market.

• NAD+ test kit enables practitioners to measure and track patient NAD+ levels for personalized protocols.

• Over 100 patents and a robust pipeline of next-generation NAD+ precursors support ongoing innovation.

Clinical research and evidence

• Over 40 human clinical studies and 500+ published scientific studies support the efficacy and safety of Niagen®.

• Clinical trials show Tru Niagen® increases NAD+ by 40-50% after 8 weeks at 300mg/day.

• Broad pharmaceutical potential with ongoing and completed studies in rare diseases, neurodegeneration, cardiovascular, liver, immune, and metabolic health.

• Two independent clinical trials demonstrated promising results for NAD+ augmentation in treating Ataxia Telangiectasia, a rare pediatric disease.

• ChromaDex External Research Program collaborates with leading global institutions to advance NAD+ science.